TCR2 Therapeutics reports positive interim results for gavo-cel in early-stage solid tumors trial
TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial of its T-cell therapy candidate gavo-cel in ... Read More
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More
ImmVira wraps up first dosing for MVR-T3011 in US and China
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product - MVR-T3011 intratumoral injection in phase 2 clinical trials both ... Read More
Liquid biopsy company ANGLE plc bags pharma services contract
UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from an undisclosed pharma company that is engaged ... Read More
Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type ... Read More
French biotech company Step Pharma raises €35m in a Series B round
Step Pharma has raised €35 million in a Series B financing round for advancing STP938, its lead CTPS1 inhibitor into clinical development for the treatment ... Read More
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
Boehringer Ingelheim has entered into a transformative €1.18 billion agreement to acquire NBE-Therapeutics, a clinical-stage biotech company based in Switzerland. This strategic acquisition is set ... Read More
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the acquisition of VelosBio, a clinical-stage biopharmaceutical company ... Read More
VelosBio initiates Phase 2 trial for ROR1-targeting antibody-drug conjugate VLS-101 in solid tumors
VelosBio, a San Diego-based biopharmaceutical company, has reached a significant milestone in the development of its investigational antibody-drug conjugate (ADC), VLS-101. The company announced that ... Read More
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More